48 results about "Injection solution" patented technology

This invention belongs to the pharmaceutical field and discloses a rubitetidine pharmaceutical composition, its preparation method, and its application. The pharmaceutical composition includes rubitetidine, an organic acid, and additives, wherein: rubitetidine has crystal forms including crystal form C and / or crystal form D; the additives include a lyophilization protectant or a solution stabilizer; the lyophilization protectant is a saccharide compound and / or its derivative; and the solution stabilizer is an alcohol compound. This invention focuses on rubitetidine crystal form C and rubitetidine crystal form D, and prepares a lyophilized rubitetidine formulation by adding specific organic acids and lyophilization protectants. This formulation exhibits good solubility and stability. Furthermore, by adding specific organic acids and solution stabilizers, a rubitetidine injection solution with similarly good solubility and stability can be prepared without adding lyophilization protectants or using a lyophilization-free process, optimizing the process steps and solving the problems of long production cycles and cumbersome reconstitution operations associated with traditional products.

The utility model relates to transfusion bottle technical field discloses a self -discharge formula glucose injection transfusion bottle bottle body, including bottle body and the pendant of fixed on bottle body, bottle body is by bottle body, bottle neck section and bottle mouth section is composed, the inner wall of bottle neck section is fixedly connected with the liquid lifting subassembly, the first envelope is equipped with in the bottle mouth section, the side wall of first envelope is fixedly connected with the support cover, one end of support cover and liquid lifting subassembly is through sliding arrangement. In the utility model, when only a small amount of glucose injection is left in the bottle body, the elasticity of the isolating sleeve makes the contraction sliding sleeve slide upward along the outer wall of the support cover, lifting the liquid level of the glucose injection in the bottle body, greatly reducing the residue of the glucose injection in the bottle body. By setting the protective cover, T-shaped column and the second through hole, the first envelope is protected and further fixed. The protective cover does not need to be removed when the infusion device needle is inserted.

This invention relates to an isosorbide dinitrate pharmaceutical composition injection and its preparation method. In addition to isosorbide dinitrate, the injection formulation also contains meglumine and glutathione. The preferred specifications are 5ml:5mg and 10ml:10mg. The isosorbide dinitrate injection prepared according to the formulation and process of this invention has the characteristics of high excipient safety, simple process, extremely high quality stability and good safety, which is significantly better than the prior art.

The application belongs to the technical field of biological medicine, and discloses a 50 ppm low-deuterium water injection and a preparation method thereof. The application realizes high-purity preparation of low-deuterium water by accurately controlling the deuterium content and optimizing a purification process, guarantees the safety, stability and drug compatibility of the injection, and enhances the clinical application performance.

The utility model discloses a single medicine injection liquid's paper support device, both sides of the support mechanism all are provided with first folding section, and the first folding section is 90 degrees bending to the inside of support mechanism, the below of first folding section is provided with second folding section, the second folding section is 90 degrees bending to the inside of support mechanism, the second folding section is located the side away from first folding section and is provided with third folding section, the third folding section is 120 degrees bending to the outside of support mechanism, the top of third folding section is provided with bonding section, the outer surface of bonding section and first folding section are fixed with glue bonding, first folding section, second folding section, third folding section and bonding section are all integrated, and the support mechanism for placing medicine injection liquid bottle takes three layers of corrugated paper as raw material, compared with the traditional material such as plastic bracket, foam, the packaging material cost is reduced greatly, and the corrugated paper is easy to obtain, and the price is low, is favorable to large -scale popularization and application.

This invention relates to the field of pharmaceutical injection technology, specifically to a neostigmine methylsulfate injection and its preparation method. The preparation method of the neostigmine methylsulfate injection of this invention includes the following steps: S1 pretreatment of water for injection, S2 preparation, S3 filtration, S4 filling and sealing, and S5 sterilization. This invention features a simple process, high yield, and low cost. It effectively reduces the generation of impurity I in the neostigmine methylsulfate injection, improves the storage stability of the product, reduces potential medication safety hazards caused by impurities, and ensures drug quality and medication safety.

The application belongs to the technical field of medicine preparation, and relates to a stable sucrose injection for medicine and a preparation method thereof. The application provides a preparation method of the stable sucrose injection for medicine, which comprises the following steps: mixing sucrose iron and initial water for injection, and then heating the mixture in a closed state at 100-105 DEG C for 1.5-2 hours; then adding iron citrate and sodium gluconate, and heating the mixture in a closed state at 150-160 DEG C for 1-3 minutes; after cooling to room temperature, adding sucrose, and then heating and evaporating the mixture at 115-120 DEG C for 1.5-2 hours; after cooling, adding water for injection to a concentration of 20 mg Fe / mL, adjusting the pH to 10.5-11.0, and then sterilizing and filtering to obtain the sucrose injection for medicine. The application aims to solve the technical problem that the injection is prone to degradation during long-term storage at high temperature.

This invention provides an injectable cefminox sodium preparation and its preparation method, belonging to the field of pharmaceutical preparation technology. The preparation, by weight, comprises: 1 part of refined cefminox sodium, 0.5 parts of sodium lactate Ringer's solution, 0.2 parts of vitamin B12 injection, 0.1-0.3 parts of a modified composite antioxidant, and 3 parts of physiological saline. The preparation method of the modified composite antioxidant is as follows: S1, add 1 part by weight of poloxamer to 20 parts by weight of distilled water and stir for 6-8 minutes to obtain a solution; S2, after passing 1 part by weight of natural vitamin C through a 100-mesh sieve, mix it into the solution obtained in S1, and sonicate for 10-15 minutes to obtain a vitamin C solution; S3, mix 0.5 parts by weight of vitamin D into the vitamin C solution obtained in S2, and sonicate for 15-20 minutes to obtain the modified composite antioxidant. The formulation of this invention exhibits excellent stability and stable content of cefminox sodium when exposed to environments of 35℃±2℃, 65%±5%RH and natural light, ensuring the safety and reliability of medication.

This invention discloses a stable nalmefene hydrochloride injection and its preparation method, relating to the field of biomedical technology. The injection consists of nalmefene hydrochloride, sodium chloride, hydrochloric acid, and water for injection, and contains no metal ion chelating agents, with a pH value controlled between 3.5 and 3.6. The method includes: preparing the solution and adjusting the pH under high-purity nitrogen protection in a solution preparation system with low metal ion introduction risk; filtering the solution through a polyethersulfone membrane with low metal leaching, and then filling it into ampoules with a vulcanized inner surface. This invention, through the systematic integration of multiple measures such as source control of the solution preparation system, inert atmosphere protection, precise pH control, surface passivation of packaging materials, and the use of high-purity materials, synergistically inhibits the metal ion catalytic oxidation of the active ingredient, ensuring that the content of the key degradation impurity II (2,2'-bisnalmefene) remains stably below the quality standard during long-term storage, solving the problem of chemical stability control of products in chelator-free formulations, and combining safety and process robustness.

The application provides a kind of medicine composition for treating muscle and bone disease and its application, belong to medical technology field.The medicine composition includes the following weight parts components: compound angelica injection 5-10 parts, kadsura injection 5-10 parts, wild medlar injection 5-10 parts, methylcobalamin injection 5-10 parts;It can also be selectively added vitamin B1 injection, vitamin B12 injection, yellow Chinese wax injection or bone peptide injection.The composition of the application is administered by acupoint injection or intramuscular injection, utilizes the synergistic effect of multiple traditional Chinese medicine injection and western medicine injection, reaches the comprehensive treatment effect of promoting blood circulation to remove blood stasis, dispelling wind to stop pain, nerve nutrition.Clinical experiments show that the application has significant effect on lumbar disc herniation, cervical spondylosis, shoulder periarthritis, knee osteoarthritis, femoral head necrosis, osteoporosis and the like, and the total effective rate is more than 95%, with fast effect, low recurrence rate, and no hormone-related side effects, suitable for patients of all ages.

This invention relates to the field of pharmaceutical analysis technology, specifically to a method for determining the content of deoxycholic acid injection. The detection method employs high-performance liquid chromatography (HPLC) with an ultraviolet (UV) detector. The HPLC chromatographic conditions are as follows: the column is an octadecylsilane-bonded silica column; the column dimensions are 4.6 × 150 mm, and the packing diameter is 3 μm; the detection wavelength is 220 nm; the mobile phase is 0.1% formic acid aqueous solution – 0.1% formic acid acetonitrile solution (42:58). Compared with existing technologies, UV detectors are more readily available than CAD detectors. This invention achieves quantitative detection of deoxycholic acid injection content by controlling the HPLC conditions of the UV detector. This method exhibits baseline stability, good specificity, accuracy, and precision, and is of significant importance for the quality control of deoxycholic acid injection.

Disclosed are a pharmaceutical composition, an aprepitant injection, and an aprepitant freeze-dried powder injection. The pharmaceutical composition comprises aprepitant, a primary stabilizer, and a secondary stabilizer, wherein the primary stabilizer comprises sodium deoxycholate and the secondary stabilizer comprises povidone. The aprepitant injection can be administered by injecting. The formulation uses a largely reduced amount of excipients, and is less irritative to an injection site, less prone to cause a hypersensitive reaction, and thus safer when being used by a patient. The formulation has good stability and can be stored and transported at room temperature, largely reducing production, storage, and transportation costs.

This invention belongs to the pharmaceutical field, specifically relating to a sodium nitroprusside injection and its preparation method. The sodium nitroprusside injection comprises the following raw materials in parts by weight: 1.5–3.5 parts sodium nitroprusside and 100 parts water for injection. This invention solves the problem of poor stability of sodium nitroprusside aqueous solutions by optimizing the formulation and preparation process without introducing other excipients. The sodium nitroprusside injection prepared by this invention is a sterile injectable preparation manufactured using modern aseptic filling technology combined with non-terminal sterilization. It not only has the advantages of direct and rapid action and high sterility assurance, but also has few adverse reactions and can be transported and stored at room temperature, thus improving the stability and safety of the product. This invention also provides its preparation method, which is simple, safe to use, and has stable quality.

The application discloses a compound amino acid injection (15-HBC) composition and a preparation method thereof, and belongs to the technical field of medicines. The compound amino acid injection (15-HBC) composition provided by the application comprises the following components in an amount of 250mL of the composition: isoleucine 1.532-2.298g, leucine 2.756-4.134g, lysine acetate 1.160-1.740g, methionine 0.500-0.750g, phenylalanine 0.640-0.960g, threonine 0.400-0.600g, tryptophan 0.180-0.270g, valine 1.772-2.658g, alanine 0.800-1.200g, arginine 1.160-1.740g, histidine 0.320-0.480g, proline 1.260-1.890g, serine 0.660-0.990g, glycine 0.660-0.990g, cysteine hydrochloride 0.040-0.060g, and appropriate amount of glacial acetic acid for pH adjustment, and the rest is injection water. The application also provides a preparation method of the compound amino acid injection (15-HBC) without sulfite antioxidant. Meanwhile, the activated carbon adsorption process is removed in the preparation, the control of raw material packages, production processes and the like is strengthened to control bacterial endotoxins, the production process is simplified, and the product quality is ensured.

The application discloses a high-stability and low-irritation oxytetracycline long-acting injection and a preparation method thereof. 2+ EDTA-2Na and sodium formaldehyde bisulfite are coordinated to stabilize, and forsythia extract reduces irritation; the pH of the finished product is 8.2-8.8. The method comprises acid pre-coordination, pre-filtration, ultrafiltration, reduction and deoxygenation (dissolved oxygen is less than or equal to 2 ppm) and 0.22 mu m terminal sterile filtration. The application realizes long-term clarification and content stability under high loading, and inhibits metal catalytic oxidation and alkali-sensitive degradation.

The application discloses a terminal sterilization mivacurium chloride injection, which comprises mixed solute mivacurium chloride and solvent injection water, and the concentration is 2.14 mg / ml, and the pH value of the mivacurium chloride injection is 3.2-3.8. Under the condition of the specific pH value, the degradation speed of the mivacurium chloride is slowed down, and the mivacurium chloride injection preparation can be subjected to high-temperature terminal sterilization. After sterilization, the impurity level of the preparation is still in a low state, so that no additional stabilizer excipient needs to be added, the stability of the mivacurium chloride injection is improved, the high-temperature sterilization operation can be tolerated, the preparation microorganism and endotoxin level are effectively controlled, and the safety of clinical medication is improved.

The present application relates to the technical field of biology, and discloses a cell preservation solution, a preparation method and preparation thereof, and a cell preservation method. The cell preservation solution contains 1-10 mL compound electrolyte glucose injection, 1-10 mL human blood albumin injection, 1-10 mL compound amino acid injection, 10-20 uM salvianolic acid B, 20-60 uM rhodioside, and 1-10 uM ginkgo biloba bilobal, and the compound electrolyte injection is supplemented. The cell preservation solution can improve the biological activity of cells and prolong the preservation time of cells in multiple ways by adding traditional Chinese medicine extracts as antioxidants, membrane stabilizers and antithrombotics in response to the excess of free radicals in the low-temperature preservation process.

The application belongs to the technical field of injection liquid, and provides a clindamycin phosphate injection solution and a preparation method thereof.The preparation method comprises the following steps: S1, 75-85 mL of water for injection is taken, (0.5-0.6) g of clindamycin phosphate is added into the water for injection, and after stirring and dissolving, a stabilizer is added, and stirring and dissolving are continued to obtain a base solution; S2, Zn-O-C bonded activated carbon is added into the base solution, the pH is adjusted to 5.3-5.5, then 15-25 mL of water for injection is added, and stirring and filtration are conducted, and the clindamycin phosphate injection solution is obtained.The content of clindamycin phosphate is increased by increasing the amount of activated carbon, so that the related substances (total impurities) are reduced.

According to an embodiment of the present disclosure, the room-temperature stable, unbuffered rocuronium injection formulation for intravenous administration comprises of 1% w / v of rocuronium bromide, a pH adjusting agent comprising hydrochloric acid at a concentration between 12.5 mMol and 20 mMol for the adjustment of pH between 3.5 to 4.5 and a quantity sufficient of water to make the formulation to 1 mL. The proposed formulation of the present disclosure is stabilized through optimization of pH of the formulation using only hydrochloric acid and / or sodium hydroxide as the pH adjusting agents without use of any buffering agents is suitable for moist heat sterilization. Further, the rocuronium injection formulation of the present disclosure contains lower than 3% of rocuronium related compound C, more preferably less than 2% over the stability period at room temperature conditions.

The invention provides a preparation method of salbutamol sulfate, a salbutamol sulfate injection and a preparation method, and belongs to the technical field of medicine preparation.The preparation method of the salbutamol sulfate comprises the steps that salbutamol is taken and acidified in a mixed solution of ethyl alcohol and diethyl ether, and the salbutamol sulfate is prepared; the preparation method of the salbutamol sulfate injection comprises the following steps: under the protection of nitrogen, taking water for injection, adding sodium chloride for dissolving, then adding citric acid monohydrate and sodium citrate dihydrate for dissolving, cooling, then adding salbutamol sulfate for dissolving, fixing the volume, filtering, filling, melting and sealing, and sterilizing to obtain the salbutamol sulfate injection. According to the preparation method of the salbutamol sulfate, the yield and the purity of the salbutamol sulfate can be effectively improved; in addition, by adding a specific amount of citric acid and sodium citrate, the formula can be simplified, and the dosage and variety of auxiliary materials are reduced, so that the adverse reaction is reduced, and the safety is improved.

This invention discloses a method, product, and application for the separation of astatine-211 in an aqueous phase based on valence state regulation. The method includes: passing a solution of astatine-211 containing a strong oxidizing acid through a sulfur-containing solid support, causing specific adsorption of positively valence astatine-211; eluting with a water-soluble reducing agent to reduce astatine-211 to astatine anions, obtaining an aqueous astatine-211 eluent. The entire process is carried out in the aqueous phase, requiring no organic solvents and avoiding radionuclide volatilization loss due to heating and evaporation. This invention also provides an eluent composition obtained by this method, sodium astatide injection, astatine-211-labeled radiotargeting drugs and their preparation methods, as well as the application of this eluent composition in the preparation of drugs for treating NIS-positive diseases. This invention achieves highly selective separation and mild, rapid elution of astatine-211, and the product exhibits excellent biocompatibility and radiation stability, and can be used directly or after simple activation to prepare targeted α-therapy drugs.

This application includes 11 similar designs, of which design 1 is designated as the basic design. The gist of design 6 is the shape of a "needleless injection component," as shown in the figure and description. The product shown in this design is used for aspirating and injecting liquid drugs. 6.1) Phase change diagram; 6.2) Phase change diagram; 6.3) Top view; 6.4) Rear view; 6.5) Perspective view; 6.6) Perspective view; 6.7) Bottom view; 6.8) Right side view; 6.9) Front view; 6.10) Left side view

This invention discloses a maripitan citrate injection and its preparation method, relating to the field of pharmaceutical formulation technology. It addresses the technical problems of existing maripitan citrate injections, such as low bioavailability, poor stability, and susceptibility to adverse reactions during injection. The maripitan citrate injection comprises maripitan citrate, TPGS-SO3H, zinc sodium EDTA, and water for injection. The mass ratio of maripitan citrate (calculated as maripitan) to TPGS-SO3H is 1:(1-2), and the mass ratio of TPGS-SO3H to zinc sodium EDTA is (100-200):(1-2). The maripitan citrate injection provided by this invention can effectively improve the bioavailability and stability of the product, while reducing adverse reactions such as injection pain.

To provide a method for preventing precipitation caused by the storage of an injection solution for boron neutron capture therapy.SOLUTION: The present invention provides a method for preventing precipitation of an injection solution for boron neutron capture therapy, the injection solution containing: p-boronophenylalanine or a pharmaceutically acceptable salt thereof; a sugar alcohol; and a pH adjusting agent, having a pH of 6.5 to 8.0 and an osmotic pressure ratio of 1.0 to 1.8, and being to be administered by intravenous drip injection.SELECTED DRAWING: None

The present invention belongs to the field of medicine and relates to use of an iron-loaded carbon nanoparticle suspension injection for combined administration. The iron-loaded carbon nanoparticle suspension injection is administered in combination with an anticancer drug to inhibit tumor growth. In the combined administration, the anticancer drug is administered orally or intravenously, and the iron-loaded carbon nanoparticle suspension injection is administered via intratumoral injection. After the iron-loaded carbon nanoparticle suspension injection is injected into a tumor, it is found that the anticancer drug administered orally or intravenously is enriched in the tumor, thereby increasing the concentration of the anticancer drug in the tumor, enabling the anticancer drug to more accurately act on the tumor site, and reducing the dose of the anticancer drug and its toxic side effects on normal cells and tissues. The combined administration of the iron-loaded carbon nanoparticle suspension injection and the anticancer drug has a synergistic effect.

The application provides a fast-acting flunixin meglumine injection and a preparation method thereof, and belongs to the technical field of veterinary medicine, and contains the following components: flunixin meglumine 5-10 (w / v) %, alpha-pyrrolidone 10-30 (w / v) %, hydrophilic solvent 0.5-1 (w / v) %, antioxidant 0.1-0.3 (w / v) % and the balance of water for injection. The application takes flunixin meglumine as the main drug, matches alpha-pyrrolidone as a solvent and a targeting guide distribution component, uses a hydrophilic solvent to assist dissolution and promote absorption, and uses an antioxidant to inhibit the oxidative degradation of the main drug, so that the dissolution and absorption rate of the main drug and the target tissue distribution efficiency can be effectively improved, the storage stability can be ensured, the bacterial endotoxin and the injection site redness rate meet the requirements, the acute inflammation and pain of livestock and poultry can be quickly and efficiently relieved, and the demand for instant intervention in large-scale breeding can be met.

This application includes 11 similar designs, of which design 1 is designated as the basic design. The gist of design 9 is the shape of a "needleless injection drug cartridge," as shown in the figures and description. The product shown in this design is used in conjunction with a needleless injection device for aspirating and injecting liquid drugs. 9.1) Top view; 9.2) Rear view; 9.3) Perspective view; 9.4) Perspective view; 9.5) Perspective view; 9.6) Bottom view; 9.7) Right side view; 9.8) Front view; 9.9) Left side view

This invention discloses a method for detecting the encapsulation efficiency of dexamethasone palmitate injection, belonging to the technical field of encapsulation efficiency detection. The method involves mixing dexamethasone palmitate injection with a solvent for extraction; the dexamethasone palmitate injection comprises a fat emulsion and free dexamethasone palmitate; after extraction, the fat emulsion and free dexamethasone palmitate are separated, and the encapsulation efficiency is calculated by quantitative analysis using HPLC; the polarity of the solvent is similar to that of the dexamethasone palmitate. This invention utilizes the principle of "like dissolves like" to develop a method for determining the encapsulation efficiency of dexamethasone palmitate injection extracted with an organic solvent. This method effectively separates the fat emulsion from the free dexamethasone palmitate while ensuring that the structure of the fat emulsion is not damaged during the measurement process, thus avoiding falsely low encapsulation efficiency due to drug leakage.

The application discloses methylprednisolone acetate suspension injection and a preparation method thereof, and belongs to the field of medicine. The preparation method of the methylprednisolone acetate suspension injection comprises the following steps: mixing water for injection and methylprednisolone raw material drugs to prepare a suspension; performing online sterilization on the suspension to obtain a sterilized suspension; mixing a solution of pyrithidium chloride with the sterilized suspension to obtain a mixed solution; performing high-shear treatment on the mixed solution to obtain a high-shear treated solution; mixing a mixed solution of polyethylene glycol 3350 and an isotonic agent with the high-shear treated solution to obtain a to-be-determined volume solution; adjusting the pH value of the to-be-determined volume solution, and then determining the volume to the full batch to obtain the methylprednisolone acetate suspension injection. The methylprednisolone acetate suspension injection in the application is suitable for commercial scale production, and has good quality, such as stability and redispersibility.